College of Pharmaceutical Science, Government T.D. Medical College, Alappuzha, Kerala, India.
Organic Chemistry Division, SAS, VIT University, Vellore, Tamil Nadu, India.
Arch Pharm (Weinheim). 2016 Aug;349(8):627-37. doi: 10.1002/ardp.201600088. Epub 2016 Jul 4.
A series of 11 indole-based chalcones (IC1-11) with various electron donating and withdrawing groups at the para position of the phenyl ring B were synthesized. All the compounds were tested for their human monoamine oxidase (hMAO)-A and hMAO-B inhibitory potencies. Most of the synthesized candidates proved to be potent and selective inhibitors of MAO-B rather than MAO-A, with a reversible and competitive mode. Among them, compound IC9 was found to be a potent inhibitor of hMAO-B with Ki = 0.01 ± 0.005 μM and a selectivity index of 120. It was found to be better than the standard drug, selegiline (hMAO-B with Ki = 0.20 ± 0.020 μM) with a selectivity index of 30.55. PAMPA assays were carried out for all the compounds in order to evaluate the capacity of the compounds to cross the blood-brain barrier. Moreover, the most potent MAO-B inhibitor, IC9, was nontoxic at 5 and 25 μM, with 95.20 and 69.17% viable cells, respectively. The lead compound IC9 has an antioxidant property of 1.18 Trolox equivalents by ABTS assay. Molecular modeling studies were performed against hMAO-B to observe binding site interactions of the lead compound.
一系列 11 种吲哚类查耳酮(IC1-11)具有各种供电子和吸电子基团在苯环 B 的对位。所有化合物均进行了人单胺氧化酶(hMAO)-A 和 hMAO-B 抑制活性测试。大多数合成候选物被证明是 MAO-B 的有效且选择性抑制剂,而不是 MAO-A,具有可逆和竞争性模式。其中,化合物 IC9 被发现是 hMAO-B 的有效抑制剂,Ki 值为 0.01 ± 0.005 μM,选择性指数为 120。它被发现优于标准药物,司来吉兰(hMAO-B 的 Ki 值为 0.20 ± 0.020 μM),选择性指数为 30.55。对所有化合物进行 PAMPA 测定,以评估化合物穿过血脑屏障的能力。此外,最有效的 MAO-B 抑制剂 IC9 在 5 和 25 μM 时无毒,分别有 95.20%和 69.17%的活细胞。先导化合物 IC9 通过 ABTS 测定具有 1.18 个 Trolox 当量的抗氧化性能。进行了针对 hMAO-B 的分子建模研究,以观察先导化合物的结合部位相互作用。